2024 年第 12 期 第 0 卷

曲妥珠单抗联合阿帕替尼治疗晚期乳腺癌的效果及安全性分析

Analysis of the efficacy and safety of trastuzumab combined with apatinib in the treatment of advanced breast cancer

作者：马上1夏海水2于德海1汤兰清3路彪3徐泽铭3王伟3

英文作者：Ma Shang1 Xia Haishui2 Yu Dehai1 Tang Lanqing3 Lu Biao3 Xu Zeming3 Wang Wei3

单位：1河北省沧州市人民医院甲乳外科，沧州061000；2河北省沧州市人民医院肿瘤内科一区，沧州061000；3河北省沧州市人民医院甲状腺头颈外科，沧州061000

英文单位：1Department of Thyroid Breast Surgery Cangzhou People′s Hospital Hebei Province Cangzhou 061000 China; 2First District of Department of Oncology Cangzhou People′s Hospital Hebei Province Cangzhou 061000 China; 3Department of Thyroid Head and Neck Surgery Cangzhou People′s Hospital Hebei Province Cangzhou 061000 China

关键词：晚期乳腺癌；曲妥珠单抗；阿帕替尼

英文关键词：Advancedbreastcancer;Trastuzumab;Apatinib

• 摘要：

• 目的 探究曲妥珠单抗联合阿帕替尼治疗晚期乳腺癌的效果与安全性。方法 选取2022年1月至2024年2月河北省沧州市人民医院收治的128例晚期乳腺癌患者，采用随机数字表法分为观察组与对照组,各64例。对照组采用曲妥珠单抗治疗，观察组在对照组基础上联合阿帕替尼治疗。比较2组临床疗效、生化指标、血清肿瘤标志物水平、生活质量以及不良反应发生情况。结果 观察组总有效率和疾病控制率均高于对照组［29.7%（19/64）比12.5%（8/64）、60.9%（39/64）比34.4%（22/64）］（χ2=5.680，P＜0.001； χ2=9.051，P=0.003）。治疗后2组血小板因子4、中期因子、癌胚抗原、组织多肽特异性抗原、糖类抗原125及糖类抗原153水平均低于治疗前，且观察组均低于对照组（均P＜0.05）。治疗后2组患者的生活质量评分均高于治疗前，且观察组高于对照组(均P<0.05)。治疗期间2组患者不良反应发生率比较差异均无统计学意义（均P>0.05）。结论 曲妥珠单抗联合阿帕替尼治疗晚期乳腺癌的效果及安全性均较好，能显著降低肿瘤标志物水平，提高患者的生活质量。

• Objective To investigate the efficacy and safety of trastuzumab combined with apatinib in the treatment of advanced breast cancer. Methods A total of 128 patients with advanced breast cancer admitted to Cangzhou People′s Hospital, Hebei Province from January 2022 to February 2024 were selected and divided into observation group and control group by random number table method, with 64 cases in each group. The control group was treated with trastuzumab, and the observation group was treated with apatinib on the basis of the control group. The clinical efficacy, biochemical indexes, serum tumor markers, quality of life and adverse reactions were compared between the two groups. Results The total effective rate and disease control rate of the observation group were higher than those of the control group ［29.7%（19/64） vs 12.5%（8/64）, 60.9%（39/64） vs 34.4%（22/64）］（χ2=5.680， P＜0.001； χ2=9.051， P=0.003）. After treatment, the levels of platelet factor 4, midkine, carcinoembryonic antigen, tissue polypeptide specific antigen, carbohydrate antigen 125 and carbohydrate antigen 153 in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group (all P<0.05). After treatment, the quality of life scores of the two groups were higher than those before treatment, and that in the observation group was higher than that in the control group (all P<0.05). During the treatment, there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion Trastuzumab combined with apatinib is effective and safe in the treatment of advanced breast cancer, which can significantly reduce the level of tumor markers and improve the quality of life of patients.